Quest Diagnostics launches pharmacogenomics testing service

Quest Diagnostics (NYSE: DGX) announced the launch of an advanced pharmacogenomic laboratory test service designed to help healthcare providers understand patients' genetic responses to select drug therapies. The service aims to assist providers in determining appropriate medication selection and dosing across multiple medical specialties.

The offering covers specialties including psychiatry, neurology, cardiology, oncology, rheumatology, pain management, and transplant recipient care. The test analyzes 17 genes and 4 HLA alleles, focusing on genes with recognized evidence of gene-drug associations and defined medical utility.

"Healthcare providers recognize the crucial, yet often complex, role that genetics can play in drug response," said Steven Keiles, General Manager US Specialty Genetics and Genomics Services at Quest Diagnostics. "Our goal for this PGx offering from Quest Diagnostics and Coriell Life Sciences is to help providers more efficiently leverage genetic insights to help guide prescription decisions and decrease trial-and-error while improving outcomes."

The service includes a Quest-delivered report with genotype and predicted phenotypic response, alongside medication guidance via a personalized report powered by Coriell Life Sciences, now InformedDNA. Clinicians will have access to GeneDose LIVE, a clinical decision support tool for comprehensive evaluation of patients' therapeutic regimens.

Patients can access testing through requisitions from their doctors at Quest's 2,000 patient service centers across the United States. The company also offers home collection services through at-home phlebotomy collection for patients who face scheduling, distance, or other barriers to in-office testing.

Quest provides an alternative testing option that includes only the genotype and predicted phenotypic response without the additional clinical decision support tools.

You May Also Be Interested In

• Stifel Starts Arrowhead Pharma (ARWR) at Buy
• Gyre Therapeutics (GYRE) files for 31.03M share offering by selling stockholders
• Penguin Solutions plans $650M convertible notes offering due 2031